SIRION Biotech GmbH is Europe’s leading commercial supplier of viral vector technologies, offering the most comprehensive portfolio of custom viral vectors at shortest timelines and with the most professional personal project management services.
The company began business in 2007 in Martinsried, Germany and since then has been changing the paradigm of viral vector supplies. SIRION vectors are being used for gene function research, preclinical target validation, gene therapy & vaccine development. SIRION technologies are licensed for several major clinical trials in Europe and US (Phases I and III).
The company is easily accessible with presence in Munich, Boston, Paris, Tokyo, Seoul and Tel Aviv. Commercial arrangements range from fee-for-service and IP-generating collaborations to milestone & licensing arrangements.
The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.